Redefining the risk of major arrhythmic events in non-ischaemic cardiomyopathy: insights from the DERIVATE-NICM study
- PMID: 40729425
- DOI: 10.1093/ehjci/jeaf198
Redefining the risk of major arrhythmic events in non-ischaemic cardiomyopathy: insights from the DERIVATE-NICM study
Abstract
Aims: Selection of the patients for implantable cardioverter defibrillator primary prevention therapy in non-ischaemic cardiomyopathy (NICM) needs to be improved. To evaluate the additional prognostic value of a new cardiac magnetic resonance (CMR) score based on late gadolinium enhancement (LGE) pattern distribution (DERIVATE Risk Score 2.0) when compared with previously published DERIVATE Risk Score 1.0, which is based solely on quantitative parameters, in a cohort of NICM patients enrolled in the DERIVATE registry.
Methods and results: One thousand three hundred and eighty-four NICM patients with chronic heart failure and left ventricular ejection fraction (LVEF) < 50% were evaluated for primary sudden cardiac death prevention therapy. Major adverse arrhythmic cardiac events (MAACEs) were the primary endpoint. During a median follow-up of 959 days, MAACE occurred in 128 (9.2%) patients. In the multivariate analyses, male gender [hazard ratio (HR): 1.605 (95% confidence interval, CI: 1.051-2.451); P = 0.028], LVEF per point % [HR: 0.977 (95% CI: 0.961-0.993); P = 0.005] and presence and location of midwall LGE [weighted HR: 1.066 (95% CI: 1.045-1.086), P < 0.001] were independent predictors of MAACE. A multi-parametric CMR-weighted predictive-derived score (DERIVATE Risk Score 2.0) provided a higher additional prognostic value vs. transthoracic echocardiography-LVEF cut-off of 35% when compared with the previous published DERIVATE Risk Score 1.0 with a net reclassification improvement of 54.52% (95% CI: 36.52-72.52%; P < 0.001). These findings were confirmed in the validation cohort.
Conclusion: The presence of midwall LGE, but also the location of scar, confers an added and independent MAACE risk to a large NICM population influencing the choice of treatment.
Keywords: cardiac magnetic resonance; heart failure; implantable cardioverter defibrillator therapy; non-ischaemic dilated cardiomyopathy.
© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
Conflict of interest: C.N.D.C. received a grant from Siemens and serves as Associate Editor, EHJ CVI. G.P. received institutional fees from General Electric, Bracco, Heartflow, Medtronic, Bayer, Bhoeringher, and serves as Senior Associate Editor, EHJ CVI. J.S. received research support from Bayer Healthcare Switzerland. U.J.S. received a grant from Astellas, Bayer, General Electric, and Siemens Healthcare, personal fees from Guerbet, speaking honorarium from Heartflow. A.V.-S. received a grant from Siemens Healthcare and personal fees from Elucid Bioimaging. The other authors have nothing to disclose.
Comment in
-
The dilemma of a correct patient selection for implantable cardioverter defibrillator in non-ischaemic cardiomyopathy.Eur Heart J Cardiovasc Imaging. 2025 Sep 30;26(10):1620-1622. doi: 10.1093/ehjci/jeaf224. Eur Heart J Cardiovasc Imaging. 2025. PMID: 40747665 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
